

New Medicines Decisions for January 2025

| fosdenopterin (Nulibry®) | | | | |
|---|--|---|-------------------------------|--|
| SMC Drug ID | Conditions | Decision | Date published on SMC Website | Date of decision / Expected date of decision |
| SMC2624 | Treatment of patients with molybdenum cofactor deficiency (MoCD) Type A. | Not routinely available as the ADTC is waiting for further advice from local clinical experts | 13/01/2025 | 07/02/2025 |
| Other Decision Specified : Ultra-orphan initial assessment | | | | |
| Web Link : https://scottishmedicines.org.uk/media/8856/umar-fosdenopterin-nulibry-final-august-2024-issued-061224-for-website.pdf | | | | |
| relugolix, estradiol, norethisterone acetate film-coated tablets (Ryeqo®) | | | | |
| SMC Drug ID | Conditions | Decision | Date published on SMC Website | Date of decision / Expected date of decision |
| SMC2666 | in adult women of reproductive age for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. | Not routinely available as there is a local preference for alternative medicines | 13/01/2025 | 20/08/2025 |
| Other Decision Specified : | | | | |
| Web Link : https://scottishmedicines.org.uk/media/8851/relugolix-ryeqo-final-dec-2024-for-website.pdf | | | | |

New Medicines Decisions for January 2025

| danicopan (Voydeya®) | | | | |
|---|---|---|--------------------------------------|---|
| SMC Drug ID | Conditions | Decision | Date published on SMC Website | Date of decision / Expected date of decision |
| SMC2675 | as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia. SMC restriction: under the advice of the national PNH service. | Available in line with national guidance | 13/01/2025 | 07/02/2025 |
| Other Decision Specified : | | | | |
| Web Link : https://scottishmedicines.org.uk/media/8849/danicopan-voydeya-final-dec-2024-for-website.pdf | | | | |
| iptacopan (Fabhalta®) | | | | |
| SMC Drug ID | Conditions | Decision | Date published on SMC Website | Date of decision / Expected date of decision |
| SMC2676 | As monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia. SMC restriction: under the advice of the national PNH service. | Not routinely available as the ADTC is waiting for further advice from local clinical experts | 13/01/2025 | 07/03/2025 |
| Other Decision Specified : | | | | |
| Web Link : https://scottishmedicines.org.uk/media/8850/iptacopan-fabhalta-final-dec-2024-amended-061224-for-website.pdf | | | | |

New Medicines Decisions for January 2025

| risankizumab (Skyrizi®) | | | | |
|--|---|---|-------------------------------|--|
| SMC Drug ID | Conditions | Decision | Date published on SMC Website | Date of decision / Expected date of decision |
| SMC2686 | for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy. | Not routinely available as the ADTC is waiting for further advice from local clinical experts | 13/01/2025 | 07/03/2025 |
| Other Decision Specified : | | | | |
| Web Link : https://scottishmedicines.org.uk/media/8852/risankizumab-skyrizi-abb-final-dec-2024-for-website.pdf | | | | |
| sirolimus (Hyftor®) | | | | |
| SMC Drug ID | Conditions | Decision | Date published on SMC Website | Date of decision / Expected date of decision |
| SMC2710 | For the treatment of adult and paediatric patients aged 6 and above with facial angiofibroma (facial AF) associated with tuberous sclerosis complex (TSC). | Not routinely available as the ADTC is waiting for further advice from local clinical experts | 13/01/2025 | 07/02/2025 |
| Other Decision Specified : | | | | |
| Web Link : https://scottishmedicines.org.uk/media/8854/sirolimus-hyftor-final-dec-2024-for-website.pdf | | | | |

| vamorolone (Agamree®) | | | | |
|--|--|---|-------------------------------|--|
| SMC Drug ID | Conditions | Decision | Date published on SMC Website | Date of decision / Expected date of decision |
| SMC2721 | treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older. | Routinely available from a specialist centre in another health board | 13/01/2025 | 07/03/2025 |
| Other Decision Specified : | | | | |
| Web Link : https://scottishmedicines.org.uk/media/8857/vamorolone-agamree-final-dec-2024-for-website.pdf | | | | |
| crovalimab (Piasky®) | | | | |
| SMC Drug ID | Conditions | Decision | Date published on SMC Website | Date of decision / Expected date of decision |
| SMC2728 | <p>as monotherapy for the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria (PNH):</p> <p>In patients with haemolysis with clinical symptom(s) indicative of high disease activity.</p> <p>In patients who are clinically stable after having been treated with a complement component 5 (C5) inhibitor for at least the past 6 months.</p> <p>SMC restriction: under the advice of the national PNH service.</p> | Not routinely available as the ADTC is waiting for further advice from local clinical experts | 13/01/2025 | 07/03/2025 |
| Other Decision Specified : | | | | |
| Web Link : https://scottishmedicines.org.uk/media/8848/crovalimab-piasky-abb-final-dec-2024-for-website.pdf | | | | |

| ublituximab (Briumvi®) | | | | |
|--|--|--|-------------------------------|--|
| SMC Drug ID | Conditions | Decision | Date published on SMC Website | Date of decision / Expected date of decision |
| SMC2731 | <p>treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.</p> <p>SMC restriction: treatment of relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.</p> | Available in line with local or regional guidance | 13/01/2025 | 07/03/2025 |
| Other Decision Specified : | | | | |
| Web Link : https://scottishmedicines.org.uk/media/8855/ublituximab-briumvi-abb-final-dec-2024-for-website.pdf | | | | |
| ciclosporin (Cequa®) | | | | |
| SMC Drug ID | Conditions | Decision | Date published on SMC Website | Date of decision / Expected date of decision |
| SMC2739 | <p>treatment of moderate-to-severe Dry Eye Disease (keratoconjunctivitis sicca) in adult patients who have not responded adequately to artificial tears.</p> <p>SMC restriction: severe keratitis in adult patients with Dry Eye Disease.</p> | Not routinely available as there is a local preference for alternative medicines | 13/01/2025 | 07/03/2025 |
| Other Decision Specified : | | | | |
| Web Link : https://scottishmedicines.org.uk/media/8847/ciclosporin-cequa-abb-final-dec-2024-for-website.pdf | | | | |

| bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) | | | | |
|--|---|--|-------------------------------|--|
| SMC Drug ID | Conditions | Decision | Date published on SMC Website | Date of decision / Expected date of decision |
| SMC2760 | Treatment of human immunodeficiency virus-1 (HIV-1) infection in paediatric patients at least 2 years of age and weighing at least 14 kg to less than 25kg without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. | Not routinely available as not recommended for use in NHS Scotland | 13/01/2025 | 18/12/2024 |
| Other Decision Specified : Non-submission | | | | |
| Web Link : https://scottishmedicines.org.uk/media/8859/bictegravir-emtricitabine-tenofovir-alafenamide-biktarvy-non-sub-final-dec-2024-for-website.pdf | | | | |
| rozanolixizumab (Rystiggo®) | | | | |
| SMC Drug ID | Conditions | Decision | Date published on SMC Website | Date of decision / Expected date of decision |
| SMC2761 | as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. | Not routinely available as not recommended for use in NHS Scotland | 13/01/2025 | 18/12/2024 |
| Other Decision Specified : Non-submission | | | | |
| Web Link : https://scottishmedicines.org.uk/media/8853/rozanolixizumab-rystiggo-non-sub-final-dec-2024-for-website.pdf | | | | |